Johnson & Johnson

NYSE:JNJ  
172.20
+0.02 (+0.01%)
5:23:00 PM EDT: $172.53 +0.33 (+0.19%)
Products

Janssen Announced New Three-Year Data From Long-Term Extension (Lte) Of Stelara (Ustekinumab) Phase 3 Unifi Study

Published: 07/09/2021 15:32 GMT
Johnson & Johnson (JNJ) - Janssen - Announced New Three-year Data From Long-term Extension (lte) of Stelara (ustekinumab) Phase 3 Unifi Study.
Janssen - Data Showed Majority Adult Patients With Moderately to Severely Active Ulcerative Colitis Stelara Sustained Symptomatic Remission Rates at Nearly 3 Years.
Janssen - Majority (96.4 Percent) of Patients in Symptomatic Remission(a) at Week 152 Were Corticosteroid-free in Study.